



# Prevalence of Extended-Spectrum $\beta$ -Lactamase-producing *Enterobacteriales* and Distribution of *bla*<sub>ESBL</sub> Genes from Patients who Underwent Abdominal Surgery

Sumalee Kondo<sup>1,\*</sup>, Anucha Apisarthanarak<sup>2</sup>, Suwanna Trakulsomboon<sup>3</sup>,  
Wannapa Bootkotr<sup>4</sup>, Chatchai Mingmalairak<sup>5</sup>, Prasit Mahawongkajit<sup>5</sup>,  
Jatupong Juntong<sup>5</sup>, Palin Limpavitayaporn<sup>5</sup>, Ekkapak Sriussadaporn<sup>5</sup>,  
Assanee Tongyoo<sup>5</sup>, Piyapong boonyasatid<sup>5</sup>, Trirat Chunsirisub<sup>5</sup>,  
Krisada Nakornchai<sup>5</sup>, Weerayut Thowprasert<sup>5</sup>, Pattarachai Kiratisin<sup>6</sup>,  
Prasit Palittapongarnpim<sup>7</sup>

<sup>1</sup>Division of Molecular Genetics and Molecular Biology, Department of Preclinical Sciences,  
Faculty of Medicine, Thammasat University, Pathum Thani 12120, Thailand

<sup>2</sup>Division of Infectious Diseases, Faculty of Medicine, Thammasat University,  
Pathum Thani 12120, Thailand

<sup>3</sup>Faculty of Medical Technology, Nakhonratchasima College, Nakhonratchasima 30000, Thailand

<sup>4</sup>Research administration office, Faculty of Medicine at Thammasat University,  
Pathum Thani 12120, Thailand

<sup>5</sup>Department of Surgery, Faculty of Medicine, Thammasat University, Pathum Thani 12120, Thailand

<sup>6</sup>Department of Microbiology, Faculty of Medicine Siriraj Hospital, Mahidol University,  
Bangkok 10700, Thailand

<sup>7</sup>Pornchai Matangkasumbut Center for Microbial Genomics, Department of Microbiology,  
Faculty of Science, Mahidol University, Bangkok 10700, Thailand

Received 21 July 2022; Received in revised form 23 November 2022;

Accepted 29 November 2022; Available online 31 December 2022

## ABSTRACT

The proliferation of extended-spectrum  $\beta$ -lactamase-producing *Enterobacteriales* (ESBL-PE) is a serious global health problem. Screening for ESBL-PE from rectal swabs of patients who underwent abdominal surgery and determination of *bla*<sub>ESBL</sub> genes were performed. *E. coli* producing the extended-spectrum  $\beta$ -lactamase enzyme (ESBL) (77.41%) and ESBL-producing *K. pneumoniae* (12.9%) were found in 31 out of 104 patients. The most prevalent *bla*<sub>ESBL</sub> in both *E. coli* and *K. pneumoniae* were *bla*<sub>TEM</sub> and *bla*<sub>OXA-2</sub>, whereas *bla*<sub>SHV</sub> was most prevalent only among *K. pneumoniae*. In contrast, *bla*<sub>CTX-M</sub> and *bla*<sub>OXA-10</sub> were the least detected in *E. coli*

and *K. pneumoniae*. The fecal ESBL producers isolated from swabs taken prior to and after abdominal surgery illustrated persistence of colonization in patients' guts. Multiple-drug resistant bacterial infections found among ESBL carriages appeared to be associated with prolonged hospitalization and underlying complex diseases. It is essential that healthcare professionals are cognizant of the importance of monitoring for the presence of these ESBL producers, and reducing both intra-abdominal surgery site infections and the spread of resistance genes in prolonged fecal ESBL carriages in high-risk patients.

**Keywords:** Abdominal surgery; *bla<sub>ESBL</sub>* genes; Colonization; ESBL producing *E. coli*; ESBL producing *K. pneumoniae*; Extended-spectrum  $\beta$ -lactamase (ESBL)-producing *Enterobacteriales*; Rectal swabs

## 1. Introduction

Extended-spectrum  $\beta$ -lactamase-producing *Enterobacteriales* (ESBL-PE) spp. have been a serious global health concern for transmission of multidrug resistance, particularly in Gram-negative bacteria such as *Escherichia coli* and *Klebsiella pneumoniae*. They have been responsible for hospital-acquired infections, including surgical site infections (SSIs), and are associated with considerable morbidity and mortality [1, 2].  $\beta$ -lactamase resistance genes are generally plasmid mediated and rapidly evolving, which leads to extended spectra of various  $\beta$ -lactam antibiotics. ESBL-producing *E. coli* (EPEC) was first associated with hospital-acquired infections and, in reports from the 2000s, it was noted as an important cause of community-acquired infections [3-5]. The community sources of bacterial transmission were associated with hospital and healthcare settings, and colonization of food and water [6, 7]. SSIs are a common form of hospital acquired infection caused by *Staphylococcus aureus*, *E. coli*, *Enterococcus* spp., *Pseudomonas aeruginosa*, and *Enterobacter* spp. Their presence has been a major concern due to the consequent increased mortality and longer hospitalization, which also leads to higher cost of treatment [8, 9]. ESBL-producing gram negative bacteria, especially *Enterobacteriales* and *P. aeruginosa*, are able to hydrolyze extended spectrum cephalosporins including ceftazidime, ceftriaxone, cefotaxime, and oxyimino-monobactam; however,  $\beta$ -lactam inhibitors such as

clavulanic acid are still available for treatment of ESBL infections [10-12].

ESBL-producing *Enterobacteriales*, particularly *E. coli* and *Klebsiella* spp., have been involved in SSIs from colonization of the throat, nose, and rectum [13-15]. This occurrence called attention to the need for careful monitoring, effective safety measures, and communicating warnings of ESBL carriage. Infection control measures, prevention of ESBL transmission, and appropriate use of antibiotics are essential for reduction of infection risk [16].

ESBL genes are horizontally transmitted by mobile genetic elements among the same, as well as different, species [5]. The use of new generations of  $\beta$ -lactams for treatment helped to enable selection pressure to generate the diversification of different antibiotic resistance mechanisms [17].

ESBL carriage had not previously been screened in patients who underwent abdominal surgery at the 750-bed tertiary-care hospital where we conducted this study. The distribution of ESBL genes was explored among the isolated strains. Detailed information regarding present strains is essential for health care professionals in the monitoring and reducing of intra-abdominal surgery site infection and the spread of resistance genes in high-risk cases of prolonged ESBL carriage.

## 2. Materials and Methods

### 2.1 Study setting and patients

Rectal swabs from 104 patients who underwent abdominal surgery at a 750-bed tertiary-care hospital between July 2018 and March 2019 were collected twice, at 1 day before and 1-3 days after abdominal surgery.

ESBL-PE detected in patients 1 day prior to abdominal surgery was considered to be colonization. The isolates were considered to be persistent when detected at both 1 day prior to and 1-3 days after surgery.

This study was approved by the Human Research Ethics Committee No. 1, Faculty of Medicine, Thammasat University, current name: Human Ethics Committee of Thammasat University (Medicine), Thailand (MTU-EC-DS-2-014/61;083/2561). All patients gave informed consent prior to the study.

### 2.2 Screening for ESBL-producing *Enterobacteriales*

Rectal swabs (in Amies transport medium) were collected from 104 patients who underwent abdominal surgery, at 1 day prior to and 1-3 days after surgery, to screen for ESBL-PE. Selective media included CHROM agar ESBL (Merck, USA) and MacConkey agar (Becton Dickinson, USA), which were used for isolation of ESBL-PE. The isolates were identified by standard biochemical tests. Combination disk diffusion test (CDT) was performed for phenotypic confirmation of the presence of ESBLs in *E. coli* and *K. pneumoniae*. Extended spectrum cephalosporin disks (Becton Dickinson, USA) were used as follows: a) a disk of 30 µg ceftazidime (CAZ) alone and a disk of CAZ with 10 µg clavulanic acid (CAZ/CLA); b) a disk of 30 µg cefotaxime (CTX) alone and a disk of CTX with 10 µg clavulanic acid (CTX/CLA). The disks mentioned above were placed on Mueller-Hinton agar (Becton Dickinson, USA) plates after inoculating the bacterial suspension (0.5 McFarland turbidity standard) and incubating at 37°C for 16-18 hours. An inhibition

zone diameter  $\geq$  5 mm on a combination disk and not on the corresponding CAZ or CTX only disk was interpreted as positive confirmation of ESBL production [18]. *E. coli* and *K. pneumoniae* strains which were resistant to either cefotaxime (inhibition zone  $\leq$  27 mm) or ceftazidime (inhibition zone  $\leq$  22 mm) with no increment of inhibition zones on either CAZ/CLA or CTX/CLA disks were interpreted as resistant strains. *K. pneumoniae* ATCC 700603, a positive control of ESBL producing bacteria, and *E. coli* ATCC 25922 were included as negative controls.

### 2.3 Detection of *bla*<sub>ESBL</sub> genes

The isolates were further examined for *bla*<sub>ESBL</sub> genes including *bla*<sub>TEM</sub>, *bla*<sub>SHV</sub>, *bla*<sub>CTX-M</sub>, *bla*<sub>OXA-2</sub>, and *bla*<sub>OXA-10</sub> by polymerase chain reaction (PCR). Primers used are as follows:

TEM-F

TCCGCTCATGAGACAAT AACC and

TEM-R TTGGTCTGACAGTTACC

AATGC for *bla*<sub>TEM</sub> (931bp) [19], SHV-F

TGGTTATGCGTTATTCG CC and

SHV-R GGTTA GCGTTGCCAGTGCT for

*bla*<sub>SHV</sub> (868bp) [20], CTX-F

TCTTCCAGAATAAGGAATCCC and

CTX-R CCGTTCCGCTATTACAAAC for *bla*<sub>CTX-M</sub> (909bp) [19], OXA-2-F

AAGAAACGCTA CTCGCCTGC and

OXA-2-R CCACTCAAC CCATCCTACCC for *bla*<sub>OXA-2</sub> group (478bp)[21], OXA-10-F

GTCTTCGAGTACGGCATTA and OXA-10-R ATTTTCTTAGCGGCAA CTTAC for

*bla*<sub>OXA-10</sub> group (720 bp) [22]. The primers and PCR conditions used are the same as described in previous reports with some modifications by using multiplex PCR. The annealing temperatures in this study were 58°C for *bla*<sub>TEM</sub>, *bla*<sub>SHV</sub>, and *bla*<sub>OXA-10</sub> and 55°C for *bla*<sub>CTX-M</sub> and *bla*<sub>OXA-2</sub>. Positive controls of all genes were included. Negative results for *bla*<sub>ESBL</sub> genes were repeated for accuracy.

### 3. Results and Discussion

#### 3.1 Isolation of *E. coli* and *K. pneumoniae*

EPEC ( $n=39$ ), ESBL-producing *K. pneumoniae* (EPKP,  $n=8$ ), resistant strains of *E. coli* (EC<sup>R</sup>,  $n=5$ ), and *K. pneumoniae* (KP<sup>R</sup>,  $n=14$ ) were detected in 36 of the 104 patients (34.6%) who underwent abdominal surgery. A total of 31 of the 104 patients (29.8%) were found to have EPEC (23 patients) and EPKP (8 patients) strains present.

In the early 2000s, ESBL carriage dramatically increased by more than 50% in

**Table 1.** Detection of EPEC, EPKP, EC<sup>R</sup>, and KP<sup>R</sup> strains isolated from rectal swab pre- and post-abdominal surgery.

Pre-surgery	Post-surgery	Patient no.	Number of strains
EPEC	EPEC	3, 4, 9, 13, 14, 17, 18, 20, 22, 23, 24, 27	12
EPEC	Not found	6, 10, 12, 19, 25, 34	6
Not found	EPEC	1, 11, 15, 16, 28, 35	6
EC <sup>R</sup>	Not found	3, 5	2
Not found	EC <sup>R</sup>	2, 35, 36	3
EPKP	Not found	7, 26, 36	3
Not found	EPKP	8, 20, 28, 30, 33	5
KP <sup>R</sup>	KP <sup>R</sup>	5, 20, 35	3
KP <sup>R</sup>	Not found	6, 32	2
Not found	KP <sup>R</sup>	30	1

#### 3.2 Laboratory data

Seventeen patients provided bacterial culture from specimens including bile, percutaneous transhepatic biliary drainage, percutaneous catheter drainage, abdominal fluid, urine, and blood. Multidrug resistant (MDR) bacterial infections were reported in ESBL carriages (8 out of 17, 47.06%). One ESBL strain isolated from patient no. 4 appeared to be MDR. Other carriages were reported with no significant infections and no bacterial growth ( $n=7$ ).

Southeast Asia, including Thailand [23]. In contrast, reports in Europe showed the lowest carriage rate at about 10% [24]. This study showed that 29.8% of the patients had EPEC and EPKP present. Similarly, ESBL producers were isolated from stool in 30.8% of healthy adults in Thailand [25].

EPEC and KP<sup>R</sup> strains isolated at both pre- and post- abdominal surgery were found from 12 and 3 patients, respectively (Table 1).

Length of hospital stay of all patients ranged from 2 to 232 days. All of the infected patients with MDR bacteria had prolonged length of hospitalization. Four of the 8 patients who had MDR bacterial infections died. All patients who died in-hospital were hospitalized longer than one and a half months. In addition, these patients had underlying complex diseases, such as malignant neoplasm of retroperitoneum, peritoneum, oesophagus, gallbladder, or rectum, and acute renal failure, as illustrated in Table 2.

**Table 2.** ESBL producers and multiple drug resistant (MDR) bacteria in ESBL carriages.

Patient No.	Age	Date of isolation	Rectal swab culture		Date of isolation	Specimen*	Isolated bacteria	Length of stay (status of treatment)	Diagnosis
			Before surgery	After surgery					
4	36	14/12/2018	SK4 EPEC	SK6 EPEC	1/1/2018 26/7/2019	PCD PCD (fluid)	KP MDR -EPEC & MDR-EC, KP, X. <i>malophilia</i> , <i>Aeromonas</i> spp. EPEC, MDR-EC, EC, KP	21 (Survive )	Cholangitis, Obstruction of bile duct
						PTBD (fluid) Blood	MDR-EC, MDR-KP, EC		
12	31	5/2/2019	SK56 EPEC	Not found	5/2/2019 - 17/2/2019	Urine Abdominal fluid	MDR-EC MDR-EC	60 (death)	Acute renal failure, of uncertain Neoplasm or un- known behavior ~ peritoneum
14	49	13/2/2019	SK82 EPEC	Not found	27/2/2019 - 12/3/2019	Urine	MDR-EC CRE-KP	81 (death)	Malignant neoplasm of oesophagus, unspecified
16	71	1/3/2019	SK87 MDR_KP	SK85 EPEC	12/3/2019	Bile Urine	MDR- <i>P. aeruginosa</i> (transferred to other hospital) KP	52	Cholangitis, Intrahepatic bile duct carcinoma
17	61	7/3/2019	SK88 EPEC	Not found	14/2/2019 - 19/6/2019	Bile PTBD (fluid) Sputum	MDR-EC MDR-EC, CRE-ECL MDR-EC	232 (death)	Secondary malignant neoplasm of retroperitoneum and peritoneum, Acute cholecystitis
19	71	8/3/2019	SK93 EPEC	Not found	18/9/2019 6/10/2020	Urine Blood	<i>E. coli</i> MDR - <i>Acinetobacter</i> <i>indicus</i> , <i>Serratia marcescens</i>	42 (survive)	Calculus of bile duct without cholangitis or cholecystitis, Urinary tract infection, site not specified
23	76	18/3/2019	SK103 EPEC	SK104 EPEC	22/7/2019	Urine	MDR-KP	33 (Survive)	Obstruction of bile duct, Malignant neoplasm of head of pancreas Acute renal failure, unspecified

25	73	12/7/2018	SK107 EPEC	Not found	9/10/2019	Bile	MDR-EC	15 (death)	Malignant neoplasm of gallbladder, Malignant neoplasm of rectum
----	----	-----------	---------------	--------------	-----------	------	--------	---------------	--

Note: \* PCD, percutaneous catheter drainage; PTBD, percutaneous transhepatic biliary drainage

As shown in Table 2, prolonged hospitalization and complex underlying diseases of ESBL carriage seemed to be associated with increased risk of MDR bacterial infection and mortality. Moreover, the persistence of ESBL-PEs in patients' guts could put them at risk of infection and cause spread of infection in hospital and community settings in the future, as has been suggested in previous reports [26, 27].

Since ESBL genes are transmissible and result in increased spread of antimicrobial resistance by natural selection [28-30], horizontal transfer of certain plasmid-mediated resistance genes is almost certain to take place [5, 31, 32]. However, further detailed exploration of ESBL gene transmission is needed. It is crucial to investigate if ESBL-PE strains cause infections in community or

healthcare settings to reinforce antimicrobial stewardship programs, infection prevention, and control measures.

### 3.3 Distribution of blaESBL genes

Regarding the results of ESBL gene detection, SHV, TEM, CTX-M, OXA-2, and OXA-10 type ESBLs were disseminated among EPEC, EPKP, and KPR strains, except for CTX-M type ESBL, which was not detected in ECR, as indicated in Table 3.

The EPEC and ECR isolates mainly possessed blaTEM and blaOXA-2, while EPKP and KPR possessed blaSHV and blaOXA-2. Strikingly, CTX-M and OXA-10 type ESBLs were the least detected in this study. OXA-10 type ESBL was found in EPKP and KPR more than it was in EPEC and EPR (Table 3).

**Table 3.** Distribution of bla<sub>ESBL</sub> genes (%) in *E. coli* and *K. pneumoniae* isolated from rectal swab.

Strains	bla <sub>SHV</sub>	bla <sub>TEM</sub>	bla <sub>CTX-M</sub>	bla <sub>OXA-2</sub>	bla <sub>OXA10</sub>
EPEC (n= 39)	30.77	87.18	43.59	89.74	15.38
EC <sup>R</sup> (n=5)	40.00	80.00	0	100.0	40.00
EPKP (n=8)	81.82	87.50	14.29	71.43	57.14
KP <sup>R</sup> (n=14)	78.57	42.86	14.29	78.57	50.00

TEM and OXA-2 type ESBLs were the most common ESBL genes found in this study while CTX-M and OXA-10 were the least found in this study. In contrast, bla<sub>CTX-M</sub> showed a significant increase in many countries, including Thailand [23, 30, 33-35]. However, the potential threat of plasmid-mediated transmission cannot be ignored, since it may lead to rapid spread and infections in cases of high-risk ESBL carriage.

From data of bla<sub>ESBL</sub> gene detection, designated resistance gene patterns of EPEC/EC<sup>R</sup> and EPKP/KP<sup>R</sup> are presented in Table 4 and Table 5, respectively. The results indicated that the EPEC isolates from patients no. 3 and 4 had the same resistance gene pattern (9a). An ECR strain was also isolated from patient no. 3, harboring bla<sub>TEM</sub> and bla<sub>OXA-2</sub>, as was found in the EPEC strain (Table 4).

Two other patients, no.17 and no. 22, had bacteria with resistance gene patterns 3a

and 5a, respectively. The resistance genes, including *bla*<sub>SHV</sub>, *bla*<sub>TEM</sub>, and *bla*<sub>OXA-2</sub> were present in pattern 3a but *bla*<sub>SHV</sub> was absent in pattern 9a. Pattern 5a strains carried *bla*<sub>TEM</sub>,

*bla*<sub>CTX-M</sub>, and *bla*<sub>OXA-2</sub>. It is remarkable that the most common pattern found among the isolates was pattern 9a (Table 4).

**Table 4.** Designated resistance gene patterns of EPEC and EC<sup>R</sup> strains.

Patient No.	Strain code	Strain	Pre (0)/post (1) surgery	<i>bla</i> <sub>SHV</sub>	<i>bla</i> <sub>TEM</sub>	<i>bla</i> <sub>CTX-M</sub>	<i>bla</i> <sub>OXA-2</sub>	<i>bla</i> <sub>OXA-10</sub>	Pattern
1	SK1	EPEC	1	+	+	+	+	-	1a
2	SK2	EC <sup>R</sup>	1	+	+	-	+	-	3a
3*	SK3	EPEC	0	+	+	-	+	-	3a
	<b>SK76</b>	<b>EPEC</b>	<b>1</b>	-	+	-	+	-	<b>9a</b>
	SK77	EPEC	1	+	+	+	+	-	1a
	<b>SK86</b>	<b>EC<sup>R</sup></b>	<b>0</b>	-	+	-	+	-	<b>9a</b>
4*	SK4	EPEC	0	-	+	-	+	-	9a
	<b>SK6</b>	<b>EPEC</b>	<b>1</b>	-	+	-	+	-	<b>9a</b>
5	SK8	EC <sup>R</sup>	0	+	+	-	+	-	3a
6	SK11	EPEC	0	-	+	-	+	-	9a
9	SK20	EPEC	0	-	+	+	+	-	5a
	SK23	EPEC	1	+	+	+	+	-	1a
10	SK45	EPEC	0	-	+	+	+	-	5a
11	SK79	EPEC	1	-	+	-	+	-	9a
12	SK56	EPEC	0	-	+	+	+	-	5a
13	SK80	EPEC	0	-	+	-	+	+	7a
	SK81	EPEC	1	-	+	+	-	-	8a
14	SK82	EPEC	0	-	+	-	-	-	11a
	SK83	EPEC	1	-	+	-	+	-	9a
15	SK84	EPEC	1	-	+	-	+	-	9a
16	SK85	EPEC	1	-	+	-	+	-	9a
17*	<b>SK88</b>	<b>EPEC</b>	<b>0</b>	+	+	-	+	-	<b>3a</b>
	<b>SK89</b>	<b>EPEC</b>	<b>1</b>	+	+	-	+	-	<b>3a</b>
18	SK91	EPEC	0	+	+	-	+	-	3a
	SK92	EPEC	1	-	+	-	+	-	9a
19	SK93	EPEC	0	-	-	-	+	-	11a
20	SK96	EPEC	0	+	-	-	+	-	4a
	SK100	EPEC	1	-	+	+	+	-	5a
22*	<b>SK101</b>	<b>EPEC</b>	<b>0</b>	-	+	+	+	-	<b>5a</b>

SK102	EPEC	1	-	+	+	+	+	-	5a
23	SK103	EPEC	0	-	-	+	+	+	10a
	SK104	EPEC	1	-	+	-	+	+	7a
24	SK105	EPEC	0	+	+	+	-	+	2a
	SK106	EPEC	1	-	+	+	+	-	5a
25	SK107	EPEC	0	-	+	-	+	-	9a
27	SK109	EPEC	0	+	+	+	+	-	1a
	SK110	EPEC	0	+	-	+	+	-	13a
	SK111	EPEC	1	+	-	-	+	-	4a
	SK112	EPEC	1	-	+	-	+	-	9a
28	SK114	EPEC	1	-	+	+	-	+	14a
34	SK137	EPEC	0	-	+	+	+	-	5a
35	SK129	EC <sup>R</sup>	1	-	-	-	+	+	12a
	SK130	EPEC	1	-	+	-	+	+	7a
36	SK133	EC <sup>R</sup>	1	-	+	-	+	-	9a

Note: \* The same designated resistance patterns found both pre- and post- surgery are indicated in bold.

**Table 5.** Designated resistance gene patterns found among EPEC, EPKP, ECR, and KPR strains.

Designated pattern	<i>blashv</i>	<i>blatem</i>	<i>blactx-m</i>	<i>blaOXA-2</i>	<i>blaOXA-10</i>	Number of isolates		
						EPEC	EPKP	EC <sup>R</sup> /KP <sup>R</sup>
1b	+	+	+	+	+	0	1	0
<b>1a*</b>	+	+	+	+	-	<b>4</b>	<b>0</b>	<b>1 KP<sup>R</sup></b>
2a	+	+	+	-	+	1	0	0
1c	+	+	+	-	-	0	0	1 KP <sup>R</sup>
2b	+	+	-	+	+	0	3	0
<b>3a*</b>	+	+	-	+	-	<b>4</b>	<b>1</b>	<b>4 KP<sup>R</sup></b> <b>2 EC<sup>R</sup></b>
3b	+	+	-	-	-	0	1	0
13a	+	-	+	+	-	1	0	0
4b	+	-	-	+	+	0	0	4 KP <sup>R</sup>
<b>4a*</b>	+	-	-	+	-	<b>2</b>	<b>0</b>	<b>1 KP<sup>R</sup></b>
5b	+	-	-	-	+	0	1	0
5a	-	+	+	+	-	8	0	0
14a	-	+	+	-	+	1	0	0
8a	-	+	+	-	-	1	0	0
7a	-	+	-	+	+	1	0	0
<b>9a*</b>	-	+	-	+	-	<b>11</b>	<b>1</b>	<b>2 EC<sup>R</sup></b>
10a	-	-	+	+	+	1	0	0
<b>11a*</b>	-	-	-	+	-	<b>2</b>	<b>0</b>	<b>1 KP<sup>R</sup></b>
<b>12a*</b>	-	-	-	+	+	<b>1</b>	<b>0</b>	<b>2 KP<sup>R</sup></b>
2c	-	-	-	-	+	0	0	1 KP <sup>R</sup>

Note: \* Different genera belonging to the same designated patterns are indicated in bold.

Interestingly, different genera appeared to have the same gene patterns, including patterns 1a, 3a, 4a, 9a, 11a, and 12a (Table 5). It is noted that patterns 3a and 9a were detected in all strains. KP<sup>R</sup> strains (patients no. 5 and 6) and EC<sup>R</sup> strains (patients no. 2 and 5),

belonging to pattern 3a, harbored the same gene pattern as detected in EPEC (patients no. 3, 17, and 18) and EPKP (patients no. 20 and 33). In addition, pattern 9a was also detected in EPEC (patients no. 3, 4, 6, 11, 14,

15, 16, 18, 25, and 27), EC<sup>R</sup> (patients no. 3 and 36), and KP<sup>R</sup> (patient no. 7).

Other patterns including 1a, 4a, and 11 were found in EPEC and KP<sup>R</sup>. Pattern 1a (patients no. 1, 3, 9, and 27), 4a (patients no. 20 and 27) and 11a (patients no. 4 and 19) in EPEC strains were found in KP<sup>R</sup> strains which carried the resistance gene pattern 1a (patient no. 16), 4a (patient no. 35), and 11a (patient no. 35). Pattern 12a was detected in EC<sup>R</sup> (patient no. 35) and KP<sup>R</sup> (patient no. 32).

EPKP strains harbored two distinct patterns, patterns 1c and 2c. We hypothesized that these prototypes most likely originated from different sources. Specifically, the prototype 1c consisted of *bla*<sub>SHV</sub>, *bla*<sub>TEM</sub>, and *bla*<sub>CTX-M</sub> belonging to class A as designated in the Ambler classification. This ESBL genotype is predominant as demonstrated in previous reports [35-37]. The *bla*<sub>SHV</sub>, *bla*<sub>TEM</sub>, and *bla*<sub>CTX-M</sub> containing strains were potentially transferable reservoirs. The other prototype (2c) contained only *bla*<sub>OXA-10</sub>, belonging to class D  $\beta$ -lactamases, which is also transferable. Emerging infection of these variants could hinder infection control measures and cause infection to spread more widely. It is encouraged to have active surveillance and infection control measures to reduce the risk of infections and to prevent transmission.

Rapid spread of ESBL-PEs and inappropriate antibiotic treatment for ESBL carriage pose a significant threat globally. For instance, enteric colonization of ESBL-PE was associated with a higher risk of deep SSI among patients who underwent colorectal surgery [38]. As a consequence of having a high risk of infection, new antibiotic treatments, transmission control, and decolonization have been studied to eradicate ESBL-PE colonization, including in SSIs, and to reduce the risk of transmission and infections. As the problem of ESBL-PE fecal colonization has been reported globally, screening for ESBL-PE carriage in those who will undergo colorectal surgery was proposed for preoperative prophylaxis but not recommended for other

abdominal surgery which might have different risks for SSIs. However, there are several factors to consider before performing fecal screening for ESBL-PE colonization [39, 40]. It was recommended to screen for ESBL-PE colonization in patients who traveled in regions with a high prevalence of ESBL-Pes or other potential risk factors such as prolonged colonization and travel-related antibiotic use. Moreover, the prevalence of ESBL-PE fecal colonization in healthy subjects and the risk factors of ESBL-PE colonization previously reported have revealed that resistance in gram negative bacteria has significantly increased [41]. Therefore, we suggest screening for fecal ESBL carriages in those who are at high risk of infections to ensure appropriate treatment for MDR bacterial infections and to prevent transmission of resistance genes.

#### 4. Conclusion

The distribution of ESBL genes seen in this study has provided detailed information which has aided recognition of rectal colonization with ESBL-producing *E. coli* and *K. pneumoniae*. The persistent colonization of ESBL producing *E. coli* and *K. pneumoniae* in the fecal flora of patients who underwent abdominal surgery could lead to transmission of resistance genes as indicated in the carriages of those who were at high risk of MDR bacterial infections. It is therefore necessary to establish and reinforce antibiotic stewardship programmes for more rigorous infection control. This awareness highlights the urgency of effective surveillance, prevention, infection control measures, and contact precaution for disseminating alerts of prolonged fecal ESBL carriages to reduce the risk of intra-abdominal SSIs from MDR ESBL-producers. As ESBL genes can spread by plasmid-mediated transmission, screening is important in order to prevent further emergence and spread, and to provide appropriate treatment. In addition, it is essential that health care professionals are cognizant of the importance of monitoring and reducing intra-

abdominal SSIs and the spread of resistance genes in cases of prolonged fecal ESBL carriage at high risk of infection.

### Acknowledgments

Gratitude is expressed to surgeon team, including Chatchai Mingmalairak, Prasit Mahawongkajit, Jatupong Juntong, Palin Limpavitayaporn, Ekkapak Sriussadaporn, Assanee Tongyoo, Piyapong Boonyasatid, Trirat Chunsirisub, Krisada Nakornchai and Weerayut Thowprasert for providing resources and Pattarachai Kiratisin for positive control of *bla<sub>ESBL</sub>* genes. Thanks to Suwanna Trakoolsomboon for her valuable feedback and providing ESBL positive control strains. We also thank to Wannapa Bootkotr for technical support, Manon Boonbangyang and Pisit Traiyasut for laboratory data support, Faculty of Medicine of Thammasat University, Thammasat University Hospital and staffs for facility support.

### Financial support

This research was supported by the Thammasat University Fund (Number 2/57/2561), Academic presentation travel fund in oversea, Thammasat University (2023) and Research Group in multidrug resistant bacteria and the antimicrobial herbal extracts, Faculty of Medicine, Thammasat University, Thailand.

### References

- [1] Rupp ME, Fey PD. Extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae: considerations for diagnosis, prevention and drug treatment. *Drugs*. 2003;63(4):353-65.
- [2] World Health Organization. Antimicrobial resistance: global report on surveillance. Geneva: WHO; 2014.
- [3] Laupland KB, Church DL, Vidakovich J, Mucenski M, Pitout JD. Community-onset extended-spectrum beta-lactamase (ESBL) producing *Escherichia coli*: importance of international travel. *J Infect*. 2008;57(6):441-8.
- [4] Seiffert SN, Hilty M, Kronenberg A, Droz S, Perreten V, Endimiani A. Extended-spectrum cephalosporin-resistant *Escherichia coli* in community, specialized outpatient clinic and hospital settings in Switzerland. *J Antimicrob Chemother*. 2013;68(10):2249-54.
- [5] Stadler T, Meinel D, Aguilar-Bultet L, Huisman JS, Schindler R, Egli A, et al. Transmission of ESBL-producing Enterobacteriaceae and their mobile genetic elements-identification of sources by whole genome sequencing: study protocol for an observational study in Switzerland. *BMJ Open*. 2018;8(2):e021823.
- [6] Kuenzli E, Jaeger VK, Frei R, Neumayr A, DeCrom S, Haller S, et al. High colonization rates of extended-spectrum  $\beta$ -lactamase (ESBL)-producing *Escherichia coli* in Swiss travellers to South Asia- a prospective observational multicentre cohort study looking at epidemiology, microbiology and risk factors. *BMC Infect Dis*. 2014;14:528.
- [7] Zurfluh K, Hächler H, Nüesch-Inderbinen M, Stephan R. Characteristics of extended-spectrum  $\beta$ -lactamase- and carbapenemase-producing Enterobacteriaceae Isolates from rivers and lakes in Switzerland. *Appl Environ Microbiol*. 2013;79(9):3021-6.
- [8] Owens CD, Stoessel K. Surgical site infections: epidemiology, microbiology and prevention. *J Hosp Infect*. 2008;70 Suppl 2:3-10.
- [9] Qadan M, Cheadle WG. Common microbial pathogens in surgical practice. *Surg Clin North Am*. 2009;89(2):295-310, vii.
- [10] Rodríguez-Baño J, Navarro MD, Retamar P, Picón E, Pascual Á.  $\beta$ -Lactam/ $\beta$ -lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum  $\beta$ -lactamase-producing *Escherichia coli*: a

post hoc analysis of prospective cohorts. *Clin Infect Dis.* 2012;54(2):167-74.

[11] Sheu CC, Lin SY, Chang YT, Lee CY, Chen YH, Hsueh PR. Management of infections caused by extended-spectrum  $\beta$ -lactamase-producing Enterobacteriaceae: current evidence and future prospects. *Expert Rev Anti Infect Ther.* 2018;16(3):205-18.

[12] Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. *Clin Microbiol Rev.* 2005;18(4):657-86.

[13] Centers for Disease Control and Prevention. Beta-Lactamase-Producing Enterobacteriaceae. In Antibiotic resistance threats in the United States, 2013. US Department of Health and Human Services Atlanta; 2013.

[14] Trung NT, Hien TT, Huyen TT, Quyen DT, Binh MT, Hoan PQ, et al. Simple multiplex PCR assays to detect common pathogens and associated genes encoding for acquired extended spectrum betalactamases (ESBL) or carbapenemases from surgical site specimens in Vietnam. *Ann Clin Microbiol Antimicrob.* 2015;14:23.

[15] Cheikh A, Belefquih B, Chajai Y, Cheikhaoui Y, El Hassani A, Benouda A. Enterobacteriaceae producing extended-spectrum  $\beta$ -lactamases (ESBLs) colonization as a risk factor for developing ESBL infections in pediatric cardiac surgery patients: "retrospective cohort study". *BMC Infect Dis.* 2017;17(1):237.

[16] Zahar JR, Blot S, Nordmann P, Martischang R, Timsit JF, Harbarth S, et al. Screening for Intestinal Carriage of Extended-spectrum Beta-lactamase-producing Enterobacteriaceae in Critically Ill Patients: Expected Benefits and Evidence-based Controversies. *Clin Infect Dis.* 2019;68(12):2125-30.

[17] Munita JM, Arias CA. Mechanisms of Antibiotic Resistance. *Microbiol Spectr.* 2016;4(2).

[18] Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Fourth Informational Supplement M100-S24. Wayne, PA, USA: CLSI; 2014.

[19] Stürenburg E, Kühn A, Mack D, Laufs R. A novel extended-spectrum beta-lactamase CTX-M-23 with a P167T substitution in the active-site omega loop associated with ceftazidime resistance. *J Antimicrob Chemother.* 2004;54(2):406-9.

[20] Pai H, Lyu S, Lee JH, Kim J, Kwon Y, Kim JW, et al. Survey of extended-spectrum beta-lactamases in clinical isolates of *Escherichia coli* and *Klebsiella pneumoniae*: prevalence of TEM-52 in Korea. *J Clin Microbiol.* 1999;37(6):1758-63.

[21] Yan JJ, Tsai SH, Chuang CL, Wu JJ. OXA-type beta-lactamases among extended-spectrum cephalosporin-resistant *Pseudomonas aeruginosa* isolates in a university hospital in southern Taiwan. *J Microbiol Immunol Infect.* 2006;39(2):130-4.

[22] Bert F, Branger C, Lambert-Zechovsky N. Identification of PSE and OXA beta-lactamase genes in *Pseudomonas aeruginosa* using PCR-restriction fragment length polymorphism. *J Antimicrob Chemother.* 2002;50(1):11-8.

[23] Sasaki T, Hirai I, Niki M, Nakamura T, Komalamisra C, Maipanich W, et al. High prevalence of CTX-M beta-lactamase-producing Enterobacteriaceae in stool specimens obtained from healthy individuals in Thailand. *J Antimicrob Chemother.* 2010;65(4):666-8.

[24] Schoevaerdts D, Verroken A, Huang TD, Frennet M, Berhin C, Jamart J, et al. Multidrug-resistant bacteria colonization amongst patients newly admitted to a geriatric unit: a prospective cohort study. *J Infect.* 2012;65(2):109-18.

[25] Pongpech P, Naenna P, Taipobsakul Y, Tribuddharat C, Srisuengfung S. Prevalence of extended-spectrum beta-lactamase and class 1 integron integrase gene intI1 in *Escherichia coli* from Thai patients and healthy adults. *Southeast Asian J Trop Med Public Health*. 2008;39(3):425-33.

[26] Overdevest I, Haverkate M, Veenemans J, Hendriks Y, Verhulst C, Mulders A, et al. Prolonged colonisation with *Escherichia coli* O25:ST131 versus other extended-spectrum beta-lactamase-producing *E. coli* in a long-term care facility with high endemic level of rectal colonisation, the Netherlands, 2013 to 2014. *Euro Surveill*. 2016;21(42).

[27] Titelman E, Hasan CM, Iversen A, Nauclér P, Kais M, Kalin M, et al. Faecal carriage of extended-spectrum  $\beta$ -lactamase-producing Enterobacteriaceae is common 12 months after infection and is related to strain factors. *Clin Microbiol Infect*. 2014;20(8):O508-15.

[28] Carattoli A. Plasmids and the spread of resistance. *Int J Med Microbiol*. 2013;303(6-7):298-304.

[29] Accogli M, Fortini D, Giufrè M, Graziani C, Dolejska M, Carattoli A, et al. IncI1 plasmids associated with the spread of CMY-2, CTX-M-1 and SHV-12 in *Escherichia coli* of animal and human origin. *Clin Microbiol Infect*. 2013;19(5):E238-40.

[30] Luvsansharav UO, Hirai I, Niki M, Sasaki T, Makimoto K, Komalamisra C, et al. Analysis of risk factors for a high prevalence of extended-spectrum  $\{\beta\}$ -lactamase-producing Enterobacteriaceae in asymptomatic individuals in rural Thailand. *J Med Microbiol*. 2011;60(Pt 5):619-24.

[31] Arpin C, Dubois V, Coulange L, André C, Fischer I, Noury P, et al. Extended-spectrum beta-lactamase-producing Enterobacteriaceae in community and private health care centers. *Antimicrob Agents Chemother*. 2003;47(11):3506-14.

[32] Piddock LJ, Walters RN, Jin YF, Turner HL, Gascoyne-Binzi DM, Hawkey PM. Prevalence and mechanism of resistance to 'third-generation' cephalosporins in clinically relevant isolates of Enterobacteriaceae from 43 hospitals in the UK, 1990-1991. *J Antimicrob Chemother*. 1997;39(2):177-87.

[33] Zeynudin A, Pritsch M, Schubert S, Messerer M, Liegl G, Hoelscher M, et al. Prevalence and antibiotic susceptibility pattern of CTX-M type extended-spectrum  $\beta$ -lactamases among clinical isolates of gram-negative bacilli in Jimma, Ethiopia. *BMC Infect Dis*. 2018;18(1):524.

[34] Bevan ER, Jones AM, Hawkey PM. Global epidemiology of CTX-M  $\beta$ -lactamases: temporal and geographical shifts in genotype. *J Antimicrob Chemother*. 2017;72(8):2145-55.

[35] Woerther PL, Angebault C, Jacquier H, Clermont O, El Mniai A, Moreau B, et al. Characterization of fecal extended-spectrum- $\beta$ -lactamase-producing *Escherichia coli* in a remote community during a long time period. *Antimicrob Agents Chemother*. 2013;57(10):5060-5066.

[36] Kluytmans-van den Bergh MF, Rossen JW, Bruijning-Verhagen PC, Bonten MJ, Friedrich AW, Vandebroucke-Grauls CM, et al. Whole-Genome Multilocus Sequence Typing of Extended-Spectrum-Beta-Lactamase-Producing Enterobacteriaceae. *J Clin Microbiol*. 2016;54(12):2919-27.

[37] Vasaikar S, Obi L, Morobe I, Bisi-Johnson M. Molecular Characteristics and Antibiotic Resistance Profiles of *Klebsiella* Isolates in Mthatha, Eastern Cape Province, South Africa. *Int J Microbiol*. 2017;2017:8486742.

[38] Dubinsky-Pertzov B, Temkin E, Harbarth S, Fankhauser-Rodriguez C, Carevic B, Radovanovic I, et al. Carriage of Extended-spectrum Beta-lactamase-producing Enterobacteriaceae and the Risk of Surgical Site Infection After Colorectal

Surgery: A Prospective Cohort Study. *Clin Infect Dis.* 2019;68(10):1699-704.

[39] Nutman A, Carmeli Y. Reply to Apisarnthanarak and Apisarnthanarak. *Clin Infect Dis.* 2020;71(8):2025.

[40] Nutman A, Temkin E, Harbarth S, Carevic B, Ris F, Fankhauser-Rodriguez C, et al. Personalized Ertapenem Prophylaxis for Carriers of Extended-spectrum  $\beta$ -Lactamase-producing Enterobacteriaceae Undergoing Colorectal Surgery. *Clin Infect Dis.* 2020;70(9):1891-7.

[41] Karanika S, Karantanos T, Arvanitis M, Grigoras C, Mylonakis E. Fecal Colonization With Extended-spectrum Beta-lactamase-Producing Enterobacteriaceae and Risk Factors Among Healthy Individuals: A Systematic Review and Metaanalysis. *Clin Infect Dis.* 2016;63(3):310-8.